Hoth Therapeutics, Inc. (HOTH) intrinsic value & 10-year financials
Hoth Therapeutics, Inc. (HOTH) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- 1353.5%
- Free cash flow (FY2025)
- —
HOTH 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$12.5M | -$0.90 | — | — | 7924.3% |
| FY2024 | — | -$8.2M | -$1.28 | — | — | 2693.1% |
| FY2023 | — | -$7.8M | -$2.30 | — | — | 1740.6% |
| FY2022 | — | -$11.4M | -$8.79 | — | — | -151.6% |
| FY2021 | — | -$14.3M | -$16.02 | — | — | -197.1% |
| FY2020 | — | -$7.2M | — | — | — | -204.4% |
| FY2019 | — | -$7.7M | — | — | — | -604.1% |
| FY2018 | — | -$2.5M | — | — | — | -372.6% |
| FY2017 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Hoth Therapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Hoth Therapeutics, Inc. returns on capital have been average, hovering around 13.5% ROIC over the decade.
Hoth Therapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Hoth Therapeutics, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.